Downregulation of miR-484 is associated with poor prognosis and tumor progression of gastric cancer

Li, Ying; Li, Yingfeng; Yao, Jie; Li, Rui; Fan, Xiaocheng

doi:10.1186/s13000-020-00946-8

Cited by 13 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric cancer (GC) is one of the most common cancers causing cancer mortality, especially in Asian populations, and poses a serious threat to human life. Recent clinical data confirmed that miR-484 was significantly downregulated in GC tissues compared to paraneoplastic tissues, and similarly, GC cell lines showed a typical decrease in miR-484 expression (35,104). Surprisingly, GC tissue miR-484 low levels were closely associated with hypodifferentiated or undifferentiated cells, distant metastasis in lymph nodes, and reduced 5-year overall survival (104).…”

Section: Gastric Cancermentioning

confidence: 87%

miR-484: A Potential Biomarker in Health and Disease

et al. 2022

View full text Add to dashboard Cite

Disorders of miR-484 expression are observed in cancer, different diseases or pathological states. There is accumulating evidence that miR-484 plays an essential role in the development as well as the regression of different diseases, and miR-484 has been reported as a key regulator of common cancer and non-cancer diseases. The miR-484 targets that have effects on inflammation, apoptosis and mitochondrial function include SMAD7, Fis1, YAP1 and BCL2L13. For cancer, identified targets include VEGFB, VEGFR2, MAP2, MMP14, HNF1A, TUSC5 and KLF12. The effects of miR-484 on these targets have been documented separately. Moreover, miR-484 is typically described as an oncosuppressor, but this claim is simplistic and one-sided. This review will combine relevant basic and clinical studies to find that miR-484 promotes tumorigenesis and metastasis in liver, prostate and lung tissues. It will provide a basis for the possible mechanisms of miR-484 in early tumor diagnosis, prognosis determination, disease assessment, and as a potential therapeutic target for tumors.

show abstract

Section: Gastric Cancermentioning

confidence: 87%

miR-484: A Potential Biomarker in Health and Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recently, the rapid rise of immunotherapy has brought a new therapeutic landscape for the patients who didn’t benefit from conventional chemotherapy, radiation or surgery ( Chivu-Economescu et al, 2018 ). However, in clinical practice, the majority of GC patients were usually still lack of effective therapeutical response to immunotherapy ( Li et al, 2020 ). Therefore, it is crucial to screen reliable index especially immunotherapy-related biological parameters that can predict the therapeutic responses to immunotherapy of GC patients.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy

Pan

Jiang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Gastric cancer (GC) was usually associated with poor prognosis and invalid therapeutical response to immunotherapy due to biological heterogeneity. It is urgent to screen reliable indices especially immunotherapy-associated parameters that can predict the therapeutic responses to immunotherapy of GC patients.Methods: Gene expression profile of 854 GC patients were collected from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets (GSE84433) with their corresponding clinical and somatic mutation data. Based on immune cell infiltration (ICI) levels, molecular clustering classification was performed to identify subtypes and ICI scores in GC patients. After functional enrichment analysis of subtypes, we further explored the correlation between ICI scores and Tumor Mutation Burden (TMB) and the significance in clinical immunotherapy response.Results: Three subtypes were identified based on ICI scores with distinct immunological and prognostic characteristics. The ICI-cluster C, associated with better outcomes, was characterized by significantly higher stromal and immune scores, T lymphocytes infiltration and up-regulation of PD-L1. ICI scores were identified through using principal component analysis (PCA) and the low ICI scores were consistent with the increased TMB and the immune-activating signaling pathways. Contrarily, the high-ICI score cluster was involved in the immunosuppressive pathways, such as TGF-beta, MAPK and WNT signaling pathways, which might be responsible for poor prognosis of GC. External immunotherapy and chemotherapy cohorts validated the patients with lower ICI scores exhibited significant therapeutic responses and clinical benefits.Conclusion: This study elucidated that ICI score could sever as an effective prognostic and predictive indicator for immunotherapy in GC. These findings indicated that the systematic assessment of tumor ICI landscapes and identification of ICI scores have crucial clinical implications and facilitate tailoring optimal immunotherapeutic strategies.

show abstract

“…27 In previous studies, miR-484 has been proved to be a tumor suppressor in several cancers, such as cervical cancer and gastric cancer. 28,29 In this study, we found that PCED1B-AS1 can function as ceRNA for miR-484 to inhibit its expression. What is more, miR-484 overexpression inhibited the proliferation and migration of ccRCC cells and EMT process.…”

Section: Discussionmentioning

confidence: 64%